文献速递中药与中成药合理使用中医内科中医骨伤

丁公藤属植物民族药学、植物化学、药理与毒理学综述

The ethnopharmacology, phytochemistry, pharmacology and toxicology of the genus Erycibe (Convolvulaceae).
PubMed 文献 · J Ethnopharmacol · 2021-06-06

该综述系统汇总1975至2020年丁公藤属(Erycibe)在民族药学、植物化学、药理与毒理学方面的研究。该属约70种,传统用于风湿痹痛、青光眼、肝病、感染及恶性肿瘤;已从5个种中分离153个化合物,涵盖香豆素、奎宁酸衍生物、黄酮、生物碱等。药理显示抗青光眼、抗关节炎、保肝、抗癌、抗炎、抗呼吸道合胞病毒及神经保护活性,但临床毒理、药代动力学与生物利用度研究仍不足。

要点

  • 丁公藤属传统用于风湿痹痛、青光眼、肝病及肿瘤等,含香豆素、生物碱等多种成分。
  • 药理研究显示抗青光眼、抗关节炎、保肝、抗癌、抗炎及神经保护等活性。
  • 含该属植物的中药制剂需临床毒理学评估,药代与生物利用度研究仍缺乏。

核心结论

  • 丁公藤属民族药学与药理数据丰富,但临床毒理、药代动力学和生物利用度研究存在缺口。
  • 需更详细的药理、毒理与临床研究评估该属替代品种及新药开发可能性。
  • 系统全面的临床前研究是评估该属提取物和化合物成药潜力的必要步骤。

研究设计与样本

  • 综述系统检索1975至2020年SciFinder Scholar、Science Direct、Web of Science、PubMed、Google Scholar、Scopus、Springer Link及CNKI等数据库。
  • 检索范围还包括中医典籍、博士与硕士论文及若干官方网站。
  • 该属约70种,主要分布于热带和亚热带亚洲至澳大利亚北部。

主要发现

  • 自1970年代以来,从丁公藤属5个种中分离出153个化合物,包括香豆素、奎宁酸衍生物、黄酮、生物碱、木脂素等。
  • 该属提取物和化合物显示抗青光眼、抗关节炎、保肝、抗癌、抗炎、抗呼吸道合胞病毒(RSV)及神经保护活性。
  • 传统与当地医学将该属多种植物用于风湿病、青光眼、多种肝病、感染性疾病及多种恶性肿瘤。

临床怎么用

  • 含丁公藤属植物的中药制剂用于临床前,应关注其临床毒理学安全性评估。
  • 临床应用需参考药代动力学与生物利用度研究,但目前该方面数据不足。

局限性

  • 含丁公藤属植物的草药制剂缺乏临床毒理学安全性研究。
  • 药代动力学与生物利用度研究不足,难以指导临床应用。
  • 该属替代品种及提取物、化合物成药可能性尚需更详细的药理、毒理与临床研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: The genus Erycibe belongs to the Convolvulaceae family that contains approximately 70 species mainly distributed from tropical and subtropical Asia to north of Australia. Several Erycibe species are traditionally used in folk medicine for the treatment of various ailments, including rheumatic arthralgia, primary glaucoma, hepatopathies, and infectious and malignant diseases. AIM OF THE REVIEW: This review aims to summarize comprehensive and updated information on traditional medicinal uses, phytochemistry, pharmacology, and toxicology of Erycibe species to provide a reference for the further research and application of the Erycibe genus. MATERIALS AND METHODS: The scientific and extensive literatures between 1975 and 2020 were systematically gathered from scientific databases such as SciFinder Scholar, Science Direct, Web of Science, PubMed, Google Scholar, Scopus, Springer Link and China National Knowledge Infrastructure (CNKI), as well as Chinese herbal classic books, PhD and MSc theses, and several official websites. RESULTS: Erycibe species have been used for the treatment of various rheumatoid diseases, glaucoma, a variety of hepatic diseases, infectious diseases and various malignancies in the traditional and local medicine. Since the 1970s, 153 compounds, including coumarins, quinic acid derivatives, flavonoids, alkaloids, lignans, and others have been isolated from five species of the Erycibe genus. Pharmacological studies have shown that these extracts and compounds from the Erycibe genus have extensive activities consistent with the traditional and local applications, such as anti-glaucoma, anti-arthritic, hepatoprotective and anti-cancer activities, as well as anti-inflammatory, anti-respiratory syncytial virus (RSV), and neuroprotective properties. CONCLUSIONS: Although there are extensive data on the genus Erycibe, certain specific gaps still exist. For herbal preparations containing Erycibe species, clinical toxicological investigation is required for the safety of these herbal preparation therapies, as well as further investigations on pharmacokinetics and bioavailability for guideline for clinical application. Furthermore, more detailed pharmacological, toxicological and clinical researches are needed to assess the alternatives to Erycibe species. Systematic and comprehensive pre-clinical studies are similarly required to estimate the possibility of extracts and compounds from the genus Erycibe with bioactivity developing into new drugs.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Fan L, Wu L, Yu XH, et al. The ethnopharmacology, phytochemistry, pharmacology and toxicology of the genus Erycibe (Convolvulaceae). J Ethnopharmacol. 2021. PMID: 34107330. doi:10.1016/j.jep.2021.114312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。